RNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Avidity Biosciences Inc (RNA) is not a strong buy for a beginner, long-term investor at this time. The technical indicators show a bearish trend, insiders are selling heavily, and the financial performance is weak. While the stock is oversold, there are no strong positive catalysts or proprietary trading signals to justify immediate investment.
The MACD is negative at -6.129, indicating bearish momentum. RSI is at 4.59, suggesting the stock is oversold. Moving averages are converging, showing no clear trend. Key support levels are far below the current price, with S1 at 18.587 and S2 at 4.429, indicating potential downside risk.
NULL identified. No significant positive news or developments directly related to Avidity Biosciences Inc.
Insiders are selling heavily, with a 200.63% increase in selling activity over the last month. The company's financials show a significant revenue drop (-71.07% YoY) and a large net loss (-$237.1 million). The broader market is also down, with the S&P 500 declining by 1.03%.
In Q4 2025, revenue dropped by 71.07% YoY to $860,000. Net income improved but remains negative at -$237.1 million, up 131.87% YoY. EPS increased to -1.54, up 92.50% YoY. Gross margin remained flat at 100%. Overall, the financials indicate poor growth and profitability.
No recent analyst rating or price target changes were provided. Wall Street sentiment appears neutral to negative based on the lack of positive catalysts and insider selling.
